Learn how the 12-year biologic exclusivity rule under the BPCIA delays biosimilar entry, impacting drug prices and patient access in the US compared to global markets.
Dec, 30 2025
Feb, 23 2026
Feb, 9 2026
Sep, 28 2025
Aug, 24 2026